Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that a patient with Acute Myelogenous Leukemia has recorded a complete response in its Phase 1b CHM CORE-NK and Vactosertib combination. …
Chimeric says cancer patient achieves complete response in CHM CORE-NK trial
October 7, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The consistent failure to speak out is degrading this critical public health program
October 8, 2024 - - Latest News -
New report reveals significant return from investment in adult vaccination
October 8, 2024 - - Latest News -
Mark Butler confirms Norgine's creation of DFMO access program
October 7, 2024 - - Latest News -
UQ spider venom heart drug moves into clinical trials
October 7, 2024 - - Latest News -
Chimeric says cancer patient achieves complete response in CHM CORE-NK trial
October 7, 2024 - - Latest News -
CSL welcomes new treatment for high-risk cardiovascular disease to the PBS
October 7, 2024 - - Latest News -
Cyclopharm signs agreement makes major progress with US veterans and defence administrations
October 6, 2024 - - Latest News